Senseonics Holdings, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SENS research report →
Range $10 – $20
Price Chart
About the company
Senseonics Holdings, Inc. operates as a medical technology enterprise, specializing in the development and commercialization of continuous glucose monitoring (CGM) systems. These innovative solutions cater to individuals with diabetes across the United States, Europe, the Middle East, and Africa.
- CEO
- Timothy T. Goodnow
- IPO
- 2015
- Employees
- 130
- HQ
- Germantown, MD, US
Get TickerSpark's AI analysis on SENS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $439.34M
- P/E
- -3.81
- PEG
- 0.15
- P/S
- 8.13
- P/B
- 7.54
- EV/EBITDA
- -4.30
- Div Yield
- 0.00%
- Gross Margin
- 58.72%
- Op Margin
- -200.99%
- Net Margin
- -204.19%
- ROE
- -186.15%
- ROIC
- -86.95%
Latest fiscal year · YoY change
- Revenue
- $35.26M+56.9%
- Gross Profit
- $15.76M+2857.4%
- Op Income
- $-68,337,000
- Net Income
- $-69,113,000+12.1%
- EPS
- $-1.66+33.6%
- OCF Growth
- +2.2%
- FCF Growth
- +3.9%
- 52W High
- $13.98
- 52W Low
- $4.79
- 50D MA
- $9.22
- 200D MA
- $7.37
- Beta
- 1.04
- RSI (14)
- 41
- Avg Volume
- 821.73K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Senseonics posted a record quarter with revenue more than doubling year over year, raised full-year guidance again, and said growth is being driven by Eversense 365 adoption, better access, and expanding pump partnerships.· November 9, 2026
- Q3 revenue hit $19.6 million, up about 140% year over year, with record new patient starts and shipment volume.
- U.S. revenue rose to $16.8 million, up about 160%; outside the U.S. revenue was $2.8 million, up about 65%.
- Gross profit was $12.1 million and gross margin was about 62%, versus $3.5 million and about 43% a year ago.
- Full-year 2026 revenue guidance was raised to $68 million to $70 million from $62 million to $66 million.
- Management highlighted Eversense 365 retention, higher DTC conversion, EON Care expansion, and two pump integrations as key growth drivers.
Third-quarter 2026 net revenue was $19.6 million, up approximately 140% from $8.1 million in Q3 2025. U.S. revenue was $16.8 million, up approximately 160% from $6.4 million, and revenue outside the U.S. was $2.8 million, up approximately 65% from $1.7 million. Through the first nine months, revenue was $45.8 million, up approximately 118% from $21 million. Gross profit was $12.1 million with gross margin of approximately 62%, versus $3.5 million and about 43% in the prior-year quarter. Net loss was $32.7 million, or $0.50 per share, compared with a net loss of $19.5 million, or $0.43 per share, a year ago. The company raised full-year revenue guidance to $68 million to $70 million from $62 million to $66 million, updated full-year gross margin guidance to north of 60%, and said Europe should be about 15% of full-year revenue. Full-year operating expenses are expected to come in slightly above the high end of the prior $150 million to $160 million range, and cash utilization is expected near the high end of the prior range, or approximately $120 million.
Tim Goodnow framed the quarter as a breakout period and repeatedly tied the results to product differentiation, especially Eversense 365’s full-year wear, accuracy, and removable transmitter. He said patient retention is exceeding plan, that most new patients are switching from other CGMs, and that the company is only beginning to tap a large market opportunity. He also emphasized the pipeline, including the upcoming Beta Bionics iLet launch, the 2027 Freedom pivotal study, and a targeted 2028 launch for the no-on-body-component system.
Rick Sullivan said the company is seeing operating leverage from higher gross profit dollars, with gross margin at about 62% in Q3 and guidance for the full year now north of 60%. He noted that the Q3 margin benefited from a higher bundled-pay mix of about 65% versus the usual roughly 60-40 split, plus initial Europe 365 sales and the in-housing of commercial operations. He also said SG&A was $32.3 million, R&D was $11.7 million, cash and investments were $126.6 million, debt under Hercules was about $56.2 million with $55 million principal outstanding, and that cash flow breakeven is expected shortly after Freedom launches, with Freedom margins expected north of 70%.
Analysts focused on fourth-quarter momentum, gross margin durability, the pace of pump-partner growth, and the outlook for 2027. Management said Q4 trends are building as expected, helped by seasonality in DTC and deductible timing, and that gross margin should stay close to Q3 because Europe should contribute for the full quarter even as the mix normalizes. On partnerships, management said Beta Bionics adds a second pump integration, conversations with other major pump companies continue, and the goal remains multiple pump options over time; it also said additional partnerships would likely come in the 2028 time period rather than immediately.
The bull case is that Senseonics is showing real commercial traction, with revenue, patient starts, and active prescribers all at record levels. Management believes retention is strong, pump compatibility is helping both new starts and reorder rates, and upcoming catalysts include the iLet launch and the Freedom program, which they describe as potentially revolutionary.
The main risks are that Europe is still early and grew slower than the U.S., while the company is still posting a sizable net loss and expects full-year operating expenses above prior guidance. Management also acknowledged that cash utilization is still around $120 million this year, and the path to breakeven depends on continued scale, improved margins, and the future Freedom launch. There is also execution risk in integrating new pump partnerships and bringing Freedom through development and a pivotal study before any 2028 launch.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 83.2%
- Shares Outstanding
- 54.78M
- Float Shares
- 45.58M
of shares held by institutions
114 13F filers
Buy/sell ratio 0.83. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Sessa Capital Im, L.P. | 4.44M | 0 |
| Blackrock, Inc. | 2.83M | ▲ 33.06K |
| Sio Capital Management, LLC | 2.29M | ▲ 698.17K |
| Vanguard Capital Management LLC | 2.21M | ▲ 430.44K |
| Vanguard Group Inc | 1.83M | ▼ 32.39M |
| Geode Capital Management, LLC | 1.12M | ▼ 8.59K |
| Ubs Group AG | 976.93K | ▼ 510.50K |
| State Street Corp | 954.68K | ▲ 443.57K |
| Masters Capital Management LLC | 800.00K | ▲ 100.00K |
| Walleye Capital LLC | 701.29K | ▲ 377.03K |
| Millennium Management LLC | 655.45K | ▲ 576.23K |
| Bank Of America Corp | 551.39K | ▲ 156.93K |
Held by 125 ETFs
Biggest fund positions in SENS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 15, 26 | Kaufman Francine | other | 10,068 |
| Nov 15, 26 | JAIN Mukul | other | 30,687 |
| Nov 15, 26 | Horton Kenneth L | other | 16,865 |
| Nov 15, 26 | HANSEN BRIAN B | other | 7,850 |
| Nov 15, 26 | Sullivan Frederick T. | other | 14,605 |
| Nov 15, 26 | Goodnow Timothy T | other | 61,198 |
| Nov 13, 26 | ROEDER DOUGLAS A | buy | 17,040.716 |
| Oct 1, 26 | Prince Douglas S | other | 815 |
| Oct 1, 26 | ROEDER DOUGLAS A | other | 1,480 |
| Oct 1, 26 | Fiorentino Edward | other | 1,418 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SENS coverage
Recent articles, reports, and earnings notes.
No research on SENS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SENS report →BBNX & SENS Launch Eversense 365 Integration With iLet Bionic Pancreas
zacks.com · Nov 17
Senseonics and Beta Bionics Launch Eversense® 365 and iLet® Bionic Pancreas Integration
globenewswire.com · Nov 16
Senseonics Revenue Surges 140% as New Pump Integration Nears Launch
marketbeat.com · Nov 11
Senseonics Holdings Sees $100 Million-Plus in 2027 Sales, Eyes New Eversense Launches
marketbeat.com · Nov 11
Senseonics Holdings, Inc. (SENS) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 10
Senseonics Holdings (SENS) Reports Q3 Loss, Beats Revenue Estimates
zacks.com · Nov 9
What Senseonics Holdings, Inc. Common Stock (SENS) Said on Its Q3 Earnings Call
marketbeat.com · Nov 9
Senseonics Holdings, Inc. Reports Third Quarter 2026 Financial Results
globenewswire.com · Nov 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.